BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32269460)

  • 1. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients.
    Jefferson M; Drake RR; Lilly M; Savage SJ; Tucker Price S; Hughes Halbert C
    Ethn Dis; 2020; 30(Suppl 1):185-192. PubMed ID: 32269460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy.
    Fowler JE; Terrell FL; Renfroe DL
    J Urol; 1996 Nov; 156(5):1714-8. PubMed ID: 8863577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.
    Leyh-Bannurah SR; Zaffuto E; Dell'Oglio P; Tian Z; Moschini M; Capitanio U; Briganti A; Montorsi F; Fisch M; Chun F; Kachanov M; Budäus L; Graefen M; Huland H; Karakiewicz PI
    Urol Int; 2019; 102(1):51-59. PubMed ID: 30481764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.
    Houterman S; Janssen-Heijnen ML; Verheij CD; Kil PJ; van den Berg HA; Coebergh JW
    Prostate Cancer Prostatic Dis; 2006; 9(2):179-84. PubMed ID: 16534509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation.
    Feldman AS; Meyer CP; Sanchez A; Krasnova A; Reznor G; Menon M; Kibel AS; Choueiri TK; Lipsitz SR; Sun M; Trinh QD
    J Urol; 2017 Nov; 198(5):1061-1068. PubMed ID: 28552709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The surgical learning curve for prostate cancer control after radical prostatectomy.
    Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
    J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Joentausta RM; Rannikko A; Murtola TJ
    Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
    Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
    Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
    Kimura M; Bañez LL; Gerber L; Qi J; Tsivian M; Freedland SJ; Satoh T; Polascik TJ; Baba S; Moul JW
    J Sex Med; 2012 Apr; 9(4):1174-81. PubMed ID: 22188861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.